EUVIMEDEUVIMED entdecken
Klinische Studie

Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center

Ana Malvar iD, Valeria Alberton, Cecilia Recalde, Ricardo Heguilen iD

Lupus · 2023-10 · 32 (12) · 1394-1401

DOI: 10.1177/09612033231204070 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Lupus, online erschienen am 27.09.2023. Verfasst von Ana Malvar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Organización Médica de Investigación, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Nephritis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lupus nephritis affects 40 to 70% of Systemic Lupus Erythematous(SLE) patients increasing their morbi-mortality; therefore, successful treatments are required to improve outcomes. Research Design and Study Sample In this paper 20 patients who participated in the BLISS LN trial at a single center (OMI) in Argentina were studied. All the patients continued Mycophenolate (MMF) treatment when the trial was finished and until a second biopsy was performed to determine the withdrawal of the immunosuppression according to the achieved clinical and histological response. Ten patients treated with MMF + Placebo versus 10 receiving MMF + Belimumab, were compared evaluating the complete clinical (CCR) and complete histological response (CHR) and the flares in each group.

Results

All the patients in the Belimumab group showed a CCR and 7 in the Placebo one; CHR was found in 9 and 5 patients of the Belimumab and Placebo group, respectively. None of the patients in the Belimumab group flared meanwhile two of the Placebo one did it.

Conclusions

Although the number of patients is insufficient to be able to draw unquestionable conclusions, adding Belimumab to the standard of care treatment with MMF would seem to increase the possibility of achieving a CCR, CHR, and a lower rate of relapses during treatment and long follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus NephritisHumansEnzyme InhibitorsImmunosuppressive AgentsKidneyStandard of CareTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Nephritisbelimumabrepeat kidney biopsy

Substanzen

Enzyme InhibitorsImmunosuppressive AgentsbelimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Organización Médica de Investigación, Buenos Aires, Argentina.
  • Nephrology Unit, Fernández Hospital, Buenos Aires, Argentina.
  • Pathology Unit, Fernández Hospital, Buenos Aires, Argentina.

ORCID-Profile: Ana Malvar, Ricardo Heguilen

Förderung

  • GSK

Zitieren

APA

Malvar, A., Alberton, V., Recalde, C., & Heguilen, R. (2023). Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus, 32(12), 1394-1401. https://doi.org/10.1177/09612033231204070

Vancouver

Malvar A, Alberton V, Recalde C, Heguilen R. Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center. Lupus. 2023;32(12):1394-1401. doi:10.1177/09612033231204070

BibTeX
@article{Malvar2023,
  author = {Malvar, Ana and Alberton, Valeria and Recalde, Cecilia and Heguilen, Ricardo},
  title = {Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A “post-hoc” analysis of participants in the BLISS-LN and open label extension study belonging to a single center},
  journal = {Lupus},
  year = {2023},
  volume = {32},
  number = {12},
  pages = {1394--1401},
  doi = {10.1177/09612033231204070}
}
Kostenlos starten →